Hemoglobin-degrading plasmepsin II is active as a monomer.

Hemoglobin-degrading plasmepsin II is active as a monomer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Hemoglobin-degrading plasmepsin II is active as a monomer. Abstract Text:

Jun Liu,Eva S Istvan,Daniel E Goldberg,

A family of aspartic proteases called plasmepsins is important for hemoglobin degradation in intraerythrocytic Plasmodium parasites. Plasmepsin II (PM II) is the best studied member of this family. PM II and its close orthologs and paralogs form homodimers with extensive interfaces in all known crystal structures. This raised the question whether the homodimer is the functional subunit of plasmepsins in solution. We have used gel filtration chromatography, site-directed mutagenesis, and analytical ultracentrifugation to study the oligomeric status of PM II in solution. Our results reveal that PM II exists mainly as a monomer in solution and that the monomer is fully functional for catalysis. A hydrophobic loop at the PM II monomer surface, which would be buried in a PM II dimer, is shown to be essential for the hemoglobin degradation capability of PM II.

Hemoglobin-degrading plasmepsin II is active as a monomer. Publishing Authors By Initials

J Liu,ES Istvan,DE Goldberg,

For similar genetic processes: mutagenesis research abstracts see: genetic processes: mutagenesis research

PUBMED ID PMID:

MEDLINE DATE:

Hemoglobin-degrading plasmepsin II is active as a monomer. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: The Journal of biological chemistry

VOLUME: 281

Page Numbers: 38682-8

Journal Abbreviation: J. Biol. Chem.

ISSN: 0021-9258

DAY: 13

MONTH: 10

YEAR: 2006

Hemoglobin-degrading plasmepsin II is active as a monomer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985121

Hemoglobin-degrading plasmepsin II is active as a monomer. Keywords Mesh Terms:

KEYWORDS: Mutagenesis

MESH TERMS: metabolism

Chemical & Substance for Abstract: Hemoglobin-degrading plasmepsin II is active as a monomer. Information

Substance Name: plasmepsin II

Registry Number: EC 3.4.23.39

Grant and Affiliation Information for Hemoglobin-degrading plasmepsin II is active as a monomer.

AFFILIATION: Departments of Molecular Microbiology and Medicine, Washington University School of Medicine, Howard Hughes Medical Institute, 660 S. Euclid Avenue, St. Louis, MO 63110, USA.

Country: United States

AGENCY: United States NIAID

GRANT: AI 47798

ACRONYM: AI

MEDLINETA: J Biol Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Hemoglobin-degrading plasmepsin II is active as a monomer Related Publications

• A combinatorial approach to minimal peptide models of a metalloprotein active site.
• A first large cohort study of personality trait stability over the 40 years between elementary school and midlife.
• A low-spin alkylperoxo-iron(III) complex with weak Fe-O and O-O bonds: implications for the mechanism of superoxide reductase.
• A role for falcilysin in transit peptide degradation in the Plasmodium falciparum apicoplast.
• Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors.
• Cytogenetic Effects of Antibodies to gamma-Interferon in Ultralow Doses.
• Diversity and evolution of West Nile virus in Illinois and the United States, 2002-2005.
• Effect of ultralow doses of antibodies to erythropoietin on antenatal and postnatal development of the offspring.
• Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle.
• Envisioning outcomes from choosing the midwifery model of perinatal care.
• Erythropoietic activity of preparations containing receptors and antibodies to erythropoietin in ultralow doses.
• Hemoglobin-degrading plasmepsin II is active as a monomer.
• Immunotropic Effects of Potentiated Antibodies to Human Interferon-gamma.
• Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population.
• Laser removal of pigmented and vascular lesions.
• Legal considerations in cosmetic laser surgery.
• Molecular probes of DNA bulges: functional assay and spectroscopic analysis.
• Nuchal translucency screening: how do women actually utilize the results?
• Optimization of HDR brachytherapy dose distributions using linear programming with penalty costs.
• Pharmacokinetics of rizatriptan tablets during and between migraine attacks.
• Probing DNA bulges with designed helical spirocyclic molecules.
• Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases.
• Reaction times of manual responses to a visual stimulus at the goal of a planned memory-guided saccade in the monkey.
• Role of peripherin/rds in vertebrate photoreceptor architecture and inherited retinal degenerations.
• Thermodynamics of carbohydrate isomerization reactions The conversion of aqueous allose to psicose.
• Thermodynamics of the conversion of aqueous xylose to xylulose.
• Timing of Diosgenin Appearance in Suspension Cultures of Dioscorea deltoidea.
• Treatment practices and outcomes of patients with established peripheral arterial disease hospitalized with acute myocardial infarction in a community setting.
• Twin study of depressive symptoms among older african-american women.
• Use of do-not-resuscitate orders in patients with kidney disease hospitalized with acute myocardial infarction.